ABSI - Absci Corporation (ABSI) Q1 2024 Earnings Call Transcript

2024-05-14 13:30:24 ET

Absci Corporation. (ABSI)

Q1 2024 Earnings Conference Call

May 14, 2024 8:30 AM ET

Company Participants

Alex Khan – Vice President, Finance and Investor Relations

Sean McClain – Founder and Chief Executive Officer

Zach Jonasson – Chief Financial Officer and Chief Business Officer

Christian Stegmann – SVP of Drug Creation

Conference Call Participants

Kripa Devarakonda – Truist Securities

George Farmer – Scotia Bank

Jacqueline Kisa – TD Cowen

Steve Dechert - KeyBanc Capital Markets

Li Chen – H.C. Wainwright

Presentation

Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Absci First Quarter 2024 Business Update Call. At this time, all participants are in a listen-only mode.

After the speakers’ presentation, there will be a question-and-answer session. [Operator instructions] Please be advised that today’s conference is being recorded. [Operator Instructions] I would like now to turn the conference over to Alex Khan, Vice President Finance and Investor Relations. Please go ahead.

Alex Khan

Thank you. Earlier today Absci released financial and operating results for the quarter ended March 31 2024. If you haven’t received this news release or if you'd like to be added to the Company's distribution list, please send an email to investors.absi.com. An archived webcast of this call will be available for replay on Absci’s Investor Relations website at investors.absci.com for at least 90 days after this call.

Joining me today are Sean McClain, Absci’s Founder and CEO; and Zach Jonasson, Chief Financial Officer and Chief Business Officer, Christian Stegmann, Absci's SVP of Drug Creation will also join for Q&A following prepared remarks.

Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of the Federal Securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated and you should not place undue reliance on forward-looking statements. ...

For further details see: